Figure 1
![Figure 1. Treatment schedules of studies AML-BFM-1998 and AML-BFM-2004 in standard-risk patients. Induction: AIE indicates cytarabine/idarubicin/etoposide or randomized with ADxE; and ADxE, cytarabine/liposomal daunorubicin/etoposide. Second induction: HAM indicates high-dose cytarabine [3 g/m2]/mitoxantrone. Consolidation: AI indicates cytarabine [0.5 g/m2]/idarubicin; and hAM, high-dose cytarabine [1 g/m2]/mitoxantrone. Intensification: HAE indicates high-dose cytarabine [3 g/m2]/etoposide; and CNS-RT, cranial irradiation.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/118/20/10.1182_blood-2011-07-364661/4/zh89991181870001.jpeg?Expires=1735823336&Signature=PbNvHjNA1-7kfJUzQhA5a8PPZst4SrczCGgzgoPhQ~NGtOygsAmm5OMpg6SlDV5AD5rGGhC2MCz6~7yA-WCM0-Hg80BtkrTxRFMtQrQS0q7XMHveNfo4W9Eg2PlVrfE8LLb5lWXx2wtP86pNDoaS1r4bydVcHFR4b054C-tKI2NwrhJz5miESjrIstDZeHEXe3zBS2gUwzCsqaLUewooDOvMZwqHezOiEEa55qbzOW1SMue0vDVcBq0ee08fQSeY7q1-lClp-O6H3H25iMctH5TGnXa8-5ueMW9iJuE3OQyvOK5R8HYnSlOLP1-hAuVWpheI6s4I6yQCxmb82QqZEQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Treatment schedules of studies AML-BFM-1998 and AML-BFM-2004 in standard-risk patients. Induction: AIE indicates cytarabine/idarubicin/etoposide or randomized with ADxE; and ADxE, cytarabine/liposomal daunorubicin/etoposide. Second induction: HAM indicates high-dose cytarabine [3 g/m2]/mitoxantrone. Consolidation: AI indicates cytarabine [0.5 g/m2]/idarubicin; and hAM, high-dose cytarabine [1 g/m2]/mitoxantrone. Intensification: HAE indicates high-dose cytarabine [3 g/m2]/etoposide; and CNS-RT, cranial irradiation.
